web analytics
4.7 C
Munich
Tuesday, November 29, 2022

A Close Look at Weed Inc(OTCMKTS:BUDZ)

Weed Inc(OTCMKTS:BUDZ) continues to trade in a range between $2 and $3 on moderate volume in recent weeks. The stock has runner in its blood making a huge move up earlier this year to highs over $15 a share.

Cannabis is a great place to be; according to a recent report from Arcview Market Research and its research partner BDS Analytics, over the next 10 years, the legal cannabis industry will see much progress around the globe and spending on legal cannabis worldwide is expected to hit $57 billion by 2027. The adult-use (recreational) market will cover 67% of the spending; medical marijuana will take up the remaining 33%. The largest group of cannabis buyers will be in North America, going from $9.2 billion in 2017 to $47.3 billion a decade later. Of course much of this hinges on how laws progress.

Weed Inc(OTCMKTS:BUDZ) bills itself as a USA-based alternative reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. subsidiaries in foreign locations.

WEED operates a wholly-owned subsidiary Sangre AT, LLC which is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. Sangre AgroTech’s world-respected team provides decades of expertise and innovation in the fields of genetics, plant biology, plant pathology, phytoecology, and sustainable and environmentally sound agricultural practices. Using annotated genomic data and newly generated phenotypic data, Sangre AgroTech will identify and isolate regions of the genome related to growth, synthesis of desired molecules, drought and pest resistance. This complex data set will be utilized in a breeding program to generate and establish new hybrid cultivars which exemplify the traits desired by the medical community.

To Find out the inside Scoop on BUDZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Last year Sangre Agrotech completed their acquisition of property in La Veta, CO., as stated in our last press release for development of its Cannabis genomic research facility, The Sangre Bioscience Center. La Veta, located in southern Colorado’s Spanish Peaks region, is the new home for Sangre AT, LLC (dba “Sangre AgroTech”), the Company’s wholly-owned subsidiary. Sangre AgroTech has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.

The site includes a 10,000+ sq. ft. building that will house the genomic research facility, a 4,000+ square foot building for plant product analytics and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which the company plans to convert into a series of small research pods. This acquisition provides WEEDS’ Sangre AgroTech with the opportunity to expand its research mission through the construction of additional research laboratories and cloning facilities.

On August 13 BUDZ said its Form S-1 resale registration statement relating to the resale of up to 8,982,015 shares of its common stock by certain selling shareholders was declared effective by the Securities and Exchange Commission on August 8, 2018 at 4pm Eastern Time.

In September BUDZ established WEED Israel (Cannabis) Ltd. as a wholly owned subsidiary of WEED Inc (USA). WEED Israel (Cannabis) Ltd. is currently in negotiations with major universities, hospitals, charitable organizations, Kibbutz, and private & public entities to create a true “SEED-TO-SALE” company from this Holy Land. WEED Israel’s goal is to educate the medical community with treatments and therapies to stop opioid dependency for military and public, to service the Israeli domestic Cannabis medical market, WEED Israel (Cannabis) Ltd. plans to work closely with the Israeli Ministry of Health, to grow its cannabis export markets.

WEED Israel (Cannabis) Ltd. President/CEO Glenn E. Martin proclaims that “At least 50% of any profits from operations in Israel will remain in Israel to create/expand new medicinal therapies & treatments for the Israeli people suffering from ailments and opioid destruction. WEED Israel looks to establish the ‘GOLD STANDARD’ model to make sure Israel receives its fair share and not to be exploited by large Canna-pharma companies from overseas.”

we have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $287 million market valuation BUDZ has $794k in the treasury, minimal assets and no revenues to date. BUDZ is an exciting story deceloping in small caps; the Company is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization whos wholly-owned subsidiary Sangre AT, LLC acquired a research facility and has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.That being said shareholders are anxiously waiting for more information from the Company especially concerning the build out of their facility. We will be updating on BUDZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BUDZ.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in BUDZ either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.